Q-omics provides the consensus-scored FAM230J profile across patient tissues and cancer cell-line models. FAM230J expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FAM230J is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, FAM230J RNA expression shows 4,282 significant pathway-activity associations, with the highest sampling consensus in THCA. Together, these results highlight HNSC, and THCA as cancer lineages where FAM230J shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM230J — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM230J survival associations across molecular data types. FAM230J RNA expression shows survival associations in the most cancer types (8), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM230J RNA expression–survival associations across cancer types. High FAM230J expression shows unfavorable associations in HNSC, KICH, SARC, ESCA and ACC, but favorable associations in THCA. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for FAM230J RNA expression.
This table summarizes FAM230J tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for FAM230J. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM230J shows higher tumor expression in THCA. The THCA box plot shows higher FAM230J RNA expression in tumor versus normal tissue (log2 FC = +0.047, t-test p < 0.001).
This table shows molecular features associated with FAM230J in patient tissues and cancer cell lines. In patient samples, FAM230J shows the broadest associations at the RNA and protein expression levels, with THCA recurring as the lineage with the largest associated feature set.
